QT prolongation represents a delay in the repolarization phase of the cardiac cycle, visible on an electrocardiogram (ECG) as a lengthened QT interval. This electrical disturbance can create a vulnerable substrate for dangerous ventricular arrhythmias, specifically Torsades de Pointes, making its identification and management a critical priority in clinical medicine. The duration of the QT interval is influenced by a complex interplay of genetic, pharmacological, and physiological factors, requiring a nuanced understanding for accurate assessment.
Understanding the QT Interval
To grasp the mechanisms behind prolongation, one must first understand the components of the QT interval. This measurement spans from the start of the QRS complex to the end of the T wave, reflecting the total time required for the ventricles to depolarize and then repolarize. Repolarization is not a uniform process; it involves distinct phases where potassium and calcium currents flow in and out of cardiac myocytes. Any factor that slows the repolarizing potassium currents or enhances the depolarizing sodium or calcium currents can effectively stretch this electrical timeline, leading to the pathological state known as QT prolongation.
Primary Genetic Causes
Beyond acquired causes, congenital long QT syndrome forms a fundamental category of etiology. These are typically inherited mutations in genes encoding cardiac ion channels, which disrupt the precise ionic currents necessary for normal repolarization. The condition is broadly categorized by the specific genetic defect, which dictates the clinical phenotype and treatment response.
LQT1 and LQT2
The most common forms are LQT1 and LQT2, accounting for the majority of cases. LQT1 mutations affect the slow-delayed rectifier potassium current (Iks), often triggered by exertion or emotional stress. In contrast, LQT2 mutations impact the rapid-delayed rectifier potassium current (Ikr), with symptoms frequently precipitated by auditory stimuli or sudden awakening. These genetic defects create a baseline electrical instability that is often unmasked by secondary stressors.
Pharmacological Triggers
A significant proportion of clinical cases are induced by medications, making pharmacologic review an essential step in any patient presenting with QT prolongation. Numerous drug classes are known to block the hERG potassium channel, thereby delaying repolarization. The risk is often dose-dependent, but individual susceptibility varies widely based on genetic background and comorbidities.
Certain antibiotics, such as macrolides (azithromycin, clarithromycin) and fluoroquinolones (levofloxacin, moxifloxacin), carry well-documented warnings regarding cardiac effects.
Antiarrhythmic drugs, including amiodarone and sotalol, directly target ion channels and require careful ECG monitoring during initiation.
Antipsychotics, such as haloperidol and ziprasidone, as well as certain antiemetics like ondansetron, are frequently implicated in hospital-acquired QT prolongation.
Electrolyte Disturbances and Metabolic Factors
Electrolyte abnormalities are among the most immediate and reversible causes of QT prolongation. Potassium, magnesium, and calcium act as critical co-factors in the cardiac action potential, and their depletion creates a permissive environment for arrhythmic events. Unlike genetic or structural heart disease, these imbalances can often be corrected rapidly, normalizing the ECG.
Hypokalemia (low potassium) increases the driving force for potassium efflux during repolarization, paradoxically slowing the process when concentrations are critically low.
Hypomagnesemia (low magnesium) independently prolongs the QT interval and lowers the threshold for Torsades de Pointes, often exacerbating the effects of hypokalemia.
While less common, severe hypocalcemia (low calcium) can also impact the plateau phase of the action potential, contributing to overall prolongation.
